From: A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
Any grade
Grades 3–4
N (%)
Anemia
12 (60)
4 (20)
Neutropenia
11 (55)
10 (50)
Thrombocytopenia
16 (80)
Febrile neutropenia
2 (10)
0
Nausea and vomiting
Pyrexia
6 (30)
Transaminase increase
3 (15)